Evidence map›Paper›PMID 26479035›Full record

ArticleNature2015

Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.

Lin Zhang, Siyuan Zhang, Jun Yao, Frank J Lowery, Qingling Zhang, Wen-Chien Huang, Ping Li, Min Li, Xiao Wang, Chenyu Zhang and 12 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 738 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
738citing papers in PubMed, 2 pooled it
51.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

738 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,149 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Review
  5. Review
  6. Review
  7. Molecular biomedicine · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

678 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 3 countries.

Lin Zhang *Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Siyuan Zhang *Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Jun YaoDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Frank J LoweryDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Qingling ZhangDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Wen-Chien HuangDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Ping LiDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Min LiDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Xiao WangDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Chenyu ZhangDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Hai WangDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Kenneth EllisDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
Mujeeburahiman CheerathodiDepartment of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Joseph H McCartyDepartment of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Diane PalmieriWoman's Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Jodi SaunusUniversity of Queensland Centre for Clinical Research, Herston, QLD 4029, AUS.
Sunil LakhaniUniversity of Queensland Centre for Clinical Research, Herston, QLD 4029, AUS.
Suyun HuangDepartment of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Aysegul A SahinDepartment of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Kenneth D AldapeDepartment of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Patricia S SteegWoman's Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Dihua YuDepartment of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center · USNational Cancer Institute · USUniversity of Queensland · AUChina Medical University · TW

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Molecular Analysis of Breast Cancer Metastasis to the BrainZIABC010538 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STEEG, PATRICIA SCHRIVER · 2009 to 2025
$17.1M
Tyrosine Kinase-Dependant and - Independent Pathways of EGFR in Breast Cancer ProP01CA099031 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUNG, MIEN-CHIE · 2003 to 2014
$11.6M
Signal Transduction by alphaVbeta8 IntegrinR01NS087635 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MCCARTY, JOSEPH H · 2014 to 2024
$3.7M
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBCR01CA112567 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, DIHUA · 2005 to 2016
$3.0M
Deciphering mechanisms of perivascular tumor cell invasion in glioblastomaR01NS078402 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MCCARTY, JOSEPH H · 2012 to 2016
$1.9M
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast CancerR01CA184836 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, DIHUA · 2015 to 2019
$1.8M
(PQD-3) Spatiotemporal Molecular Interrogation of Early Metastatic Evolution In SituR01CA194697 · NCI · UNIVERSITY OF NOTRE DAME · PI ZHANG, SIYUAN · 2015 to 2018
$1.4M
Dissecting the Role of Src Family Kinases in Breast Cancer Brain MetastasisR00CA158066 · NCI · UNIVERSITY OF NOTRE DAME · PI ZHANG, SIYUAN · 2012 to 2014
$707k
NCI NIH HHS 5R00CA158066-05NCI NIH HHS P01 CA099031NCI NIH HHS P01-CA099031NCI NIH HHS P30 CA016672NCI NIH HHS R00 CA158066NCI NIH HHS R01 CA112567NCI NIH HHS R01-CA112567-06NCI NIH HHS R01 CA184836NCI NIH HHS R01CA184836NCI NIH HHS R01 CA194697NINDS NIH HHS R01 NS078402NINDS NIH HHS R01 NS087635
6 · The paper itself

Abstract

The development of life-threatening cancer metastases at distant organs requires disseminated tumour cells' adaptation to, and co-evolution with, the drastically different microenvironments of metastatic sites. Cancer cells of common origin manifest distinct gene expression patterns after metastasizing to different organs. Clearly, the dynamic interaction between metastatic tumour cells and extrinsic signals at individual metastatic organ sites critically effects the subsequent metastatic outgrowth. Yet, it is unclear when and how disseminated tumour cells acquire the essential traits from the microenvironment of metastatic organs that prime their subsequent outgrowth. Here we show that both human and mouse tumour cells with normal expression of PTEN, an important tumour suppressor, lose PTEN expression after dissemination to the brain, but not to other organs. The PTEN level in PTEN-loss brain metastatic tumour cells is restored after leaving the brain microenvironment. This brain microenvironment-dependent, reversible PTEN messenger RNA and protein downregulation is epigenetically regulated by microRNAs from brain astrocytes. Mechanistically, astrocyte-derived exosomes mediate an intercellular transfer of PTEN-targeting microRNAs to metastatic tumour cells, while astrocyte-specific depletion of PTEN-targeting microRNAs or blockade of astrocyte exosome secretion rescues the PTEN loss and suppresses brain metastasis in vivo. Furthermore, this adaptive PTEN loss in brain metastatic tumour cells leads to an increased secretion of the chemokine CCL2, which recruits IBA1-expressing myeloid cells that reciprocally enhance the outgrowth of brain metastatic tumour cells via enhanced proliferation and reduced apoptosis. Our findings demonstrate a remarkable plasticity of PTEN expression in metastatic tumour cells in response to different organ microenvironments, underpinning an essential role of co-evolution between the metastatic cells and their microenvironment during the adaptive metastatic outgrowth. Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients.

Indexed as

Gene Expression Regulation, NeoplasticGene SilencingTumor MicroenvironmentAdaptation, PhysiologicalAnimalsAstrocytesBrainBrain NeoplasmsCalcium-Binding ProteinsCell ProliferationChemokine CCL2DNA-Binding ProteinsDown-RegulationEvolution, MolecularExosomesFemaleAIF1 protein, humanCalcium-Binding ProteinsChemokine CCL2DNA-Binding ProteinsMicrofilament ProteinsMicroRNAsPTEN PhosphohydrolasePTEN protein, humanRNA, MessengerTumor Suppressor Proteins

Identifiers

PMID26479035
PMCPMC4819404
OpenAlexW2169465106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.